|Authors||Aravinthan AD, Doyle AC, Issachar A, Dib M, Peretz D, Cattral MS, Ghanekar A, McGilvray ID, Selzner M, Greig PD, Grant DR, Selzner N, Lilly LB, Renner EL|
|Journal||Am. J. Transplant.|
|Publish Date||2016 Apr 18|
Liver transplantation (LT) is the treatment of choice for end-stage autoimmune liver diseases. However, the underlying disease may recur in the graft in some 20% of cases. The aim of this study is to determine whether LT using living donor grafts from first-degree relatives results in higher rates of recurrence than grafts from more distant/unrelated donors. 263 patients, who underwent a first LT in the Toronto liver transplant program between January 2000 and March 2015 for autoimmune liver diseases, and had at least 6 months of post-LT follow-up, were included in this study. Of these, 72 (27%) received a graft from a first-degree living-related donor, 56 (21%) from a distant/unrelated living donor and 135 (51%) from a deceased donor for PSC (n=138, 52%), PBC (n=69, 26%), AIH (n=44, 17%) and overlap syndromes (n=12, 5%). Recurrence occurred in 52 (20%) patients. Recurrence rates for each autoimmune liver disease were not significantly different after first-degree living-related, living unrelated or deceased donor LT. Similarly, time to recurrence, recurrence-related graft failure, graft survival and patient survival were not significantly different between groups. In conclusion, first-degree living-related donor LT for PSC, PBC or AIH is not associated with an increased risk of disease recurrence. This article is protected by copyright. All rights reserved.